The content on this site is intended for healthcare professionals only
Dr Enrique Sanz-Garcia speaks to ecancer about the MERIDIAN phase II trial.
He explores findings from the study investigating minimal residual disease interception using rilvegostomig, a TIGIT/PD-1 bispecific antibody, in patients with locally advanced head and neck cancer.
The study demonstrates the feasibility of using circulating tumour DNA to identify patients at high risk of recurrence following definitive treatment.
Early results provide proof of concept that targeting molecular residual disease may delay or prevent clinical progression.
Dr Sanz-Garcia says that although the study faced challenges with lower-than-expected detection rates of minimal residual disease, these findings support further investigation of ctDNA-guided treatment strategies and highlight the potential of early intervention in high-risk head and neck cancer.
ESMO 2026: Advances in NMIBC and MIBC
Amivantamab in HPV-unrelated mHNSCC gives high response rates after immunotherapy and chemo
Pimicotinib in TGCT demonstrates durable responses and sustained functional improvement
Key insights from head and neck research at ASCO 2025
Penpulimab in combination with chemotherapy for metastatic nasopharyngeal cancer shows positive results
Addition of pembrolizumab to standard care shows promising results in advanced head and neck cancer
Dermatologic adverse events in the treatment of NSCLC with amivantamab plus lazertinib significantly reduced
Everolimus plus lanreotide might be a new standard treatment in the first-line setting for grade 1/2 GEP-NETs
Gemcitabine/nab-paclitaxel compared with 5-fluorouracil/leucovorin/liposomal irinotecan shows similar results in older patients
